Growth Hormone Pulsatility: The Biology Behind GH Secretagogue Research

A simple fact is missing from most popular discussions of growth hormone: it isn't secreted at a steady level. It comes out in bursts. The pattern of secretion is biologically meaningful — and the pattern, not the absolute amount, is what most secretagogue research is actually trying to characterize.

Growth hormone biology basics

Growth hormone (GH), also called somatotropin, is a single-chain polypeptide of 191 amino acids, synthesized and secreted by a specialized population of cells in the anterior pituitary gland (the front lobe of the pea-sized gland at the base of the brain) called somatotrophs. Somatotrophs comprise roughly 35–45% of the total cell population of the anterior lobe and store GH in dense secretory granules, ready for release on demand.

Circulating GH binds the growth hormone receptor (GHR), a member of the class I cytokine receptor family, expressed most abundantly on hepatocytes (liver cells) but present on many other cell types. Receptor engagement activates JAK2 tyrosine kinase, which phosphorylates STAT5 and drives transcription of GH-responsive genes. The dominant downstream target is insulin-like growth factor 1 (IGF-1), produced primarily by the liver and widely considered the major mediator of GH's anabolic (tissue-building) and growth-promoting effects (Le Roith et al., 2001).

Much of the biology traditionally attributed to "GH" is in practice a composite of direct GH effects, IGF-1 effects, and local autocrine/paracrine IGF-1 produced in the target tissue itself. Disentangling the three has occupied endocrinologists for decades.

Why pulsatile secretion?

If you sample a subject's blood every few minutes for 24 hours and measure GH at each time point, you do not see a smooth curve. You see a series of sharp spikes separated by long intervals of almost undetectable GH. In healthy young adults, the largest and most consistent spikes occur during slow-wave sleep. Between spikes, GH levels can be lower than the detection limit of standard assays.

This pulsatile pattern is not an artifact. It is tightly regulated and physiologically important. The characteristics of the pattern include:

• Circadian component — the largest GH pulses of the 24-hour period occur in the first few hours of sleep, coinciding with slow-wave (stage 3) sleep.
• Ultradian component — superimposed on the circadian rhythm, smaller pulses occur roughly every 3 to 5 hours throughout the day, with sex differences in amplitude and frequency well-documented in both rodents and humans (Veldhuis et al., 1987).
• Sex-specific patterning — male rodents show high-amplitude, widely spaced GH pulses; females show more frequent, lower-amplitude pulses with a higher interpulse baseline. These patterns drive sexually dimorphic gene expression in the liver.

Receptor desensitization

The functional reason for pulsatility appears to be that target tissues respond to the change in GH concentration, not to the absolute level. Continuous exposure to GH at a constant level leads to internalization and downregulation of GHR on target cells, blunting the response. Pulsatile exposure allows receptors to reset between pulses and respond robustly to each new one. Classic experiments in hypophysectomized rats (rats whose pituitary gland had been surgically removed) demonstrated that pulsatile GH infusion restored growth substantially more effectively than continuous infusion of the same total dose (Jansson et al., 1985).

This is the key insight that animates most GH secretagogue research: how GH rises matters, and a drug regimen that mimics physiological pulses may produce effects that a continuous supply cannot.

The GHRH–ghrelin axis

The pulsatile release of GH from somatotrophs is controlled by an elegant dual-input system. Two stimulatory signals and one inhibitory signal, released rhythmically from the hypothalamus and the periphery, together generate the observed pattern.

GHRH (growth hormone releasing hormone)

GHRH is a 44-amino-acid peptide synthesized by neurons in the arcuate nucleus of the hypothalamus (a small region at the base of the brain that controls the pituitary) and released into the hypophyseal portal circulation (a dedicated short blood system that carries hormones directly from hypothalamus to pituitary). It binds the GHRH receptor (GHRHR), a G-protein-coupled receptor on somatotrophs, activating adenylate cyclase and raising intracellular cAMP. GHRH stimulates both GH synthesis and release. Mutations in the GHRH receptor cause a form of isolated growth hormone deficiency in humans and in the "little" mouse (Mayo et al., 1995).

Ghrelin and the GHSR receptor

For almost two decades after GHRH's discovery, a second pathway was suspected on pharmacological grounds but had no known endogenous ligand. Cyril Bowers at Tulane had synthesized a series of enkephalin-derived peptides, called growth hormone releasing peptides (GHRPs), that powerfully stimulated GH release but did not act through the GHRH receptor. They acted through a distinct "growth hormone secretagogue receptor" (GHSR) for which no endogenous ligand was known (Bowers et al., 1984).

The endogenous ligand was finally identified in 1999 by Kojima and colleagues: ghrelin, a 28-amino-acid peptide produced mainly by the X/A-like cells of the stomach (Kojima et al., 1999). Ghrelin circulates in the blood, crosses into the hypothalamus, and binds GHSR on somatotrophs, triggering calcium-dependent GH release through the phospholipase C pathway.

GHRH–ghrelin synergy

The striking pharmacological observation — reported long before ghrelin was identified — is that GHRH and GHRP act synergistically on GH release. Administering both together produces a GH response larger than the sum of their individual effects. Bowers and colleagues documented this synergy in the early 1990s and proposed it as evidence of two independent physiological control systems converging on the somatotroph (Bowers et al., 1990). The discovery of ghrelin later confirmed that interpretation.

Somatostatin inhibition

Opposing both GHRH and ghrelin is somatostatin, a 14-amino-acid peptide produced by neurons in the periventricular nucleus of the hypothalamus. Somatostatin tonically inhibits GH release, and the observed pulses of GH correspond to periods when somatostatin tone is transiently reduced and GHRH is released in coincident bursts. GH pulsatility is, in effect, a two-signal pattern generator implemented by the interaction of GHRH and somatostatin.

Measuring GH pulsatility

Characterizing a pulsatile hormone is an inherently harder statistical problem than measuring a steady-state one. A single blood draw tells you essentially nothing about 24-hour GH dynamics, because it is overwhelmingly likely to capture an interpulse trough. Proper characterization requires dense sampling over many hours.

Frequent sampling studies

The gold standard is a 24-hour sampling study with blood drawn every 5 to 20 minutes via indwelling catheter. This produces a time series that can be analyzed for pulse frequency, amplitude, mean concentration, and temporal structure. Such studies are labor-intensive and expensive, which limits sample sizes.

Deconvolution analysis

Johannes Veldhuis and colleagues developed and refined the method that dominates the field: deconvolution analysis, a mathematical technique that separates an observed hormone time series into a secretion profile and an elimination kinetics profile. The method assumes that observed hormone concentrations are the sum of secretion bursts convolved with a known elimination curve, and it fits both components simultaneously (Veldhuis et al., 1987).

Deconvolution yields estimates of pulse number, pulse mass (amount of hormone secreted per burst), and basal (nonpulsatile) secretion. It remains the standard tool for quantifying endocrine pulsatility in humans (Veldhuis, 2008).

Approximate entropy

A complementary technique, also developed by Veldhuis's group with Pincus, is approximate entropy (ApEn), a measure of the regularity of a time series. ApEn captures the idea that physiological hormone patterns have a characteristic level of orderliness, and that disease states or pharmacological interventions can alter that orderliness in measurable ways.

Overnight GH profiles

A pragmatic shortcut used in many studies is to sample only during the overnight period, when the largest GH pulses occur. This reduces cost and still captures the dominant physiologically meaningful secretion.

Research compounds in this space

A number of peptides have been studied as GH secretagogues — compounds that act on the GHRH or GHSR pathways to stimulate GH release. The classical examples:

CJC-1295 (GHRH analog)

CJC-1295 is a synthetic analog of GHRH (1–29) with amino-acid substitutions that resist enzymatic degradation. A further variant incorporates a maleimidopropionyl-lysine group enabling covalent conjugation to serum albumin, extending the half-life from minutes to days. Published Phase 1 studies in healthy adults reported sustained elevations in mean GH and IGF-1 concentrations over one to two weeks after a single dose (Teichman et al., 2006). Subsequent work from the Frohman group reported on the pharmacology and receptor behavior of the compound (Ionescu & Frohman, 2006).

Notably, the published profile of CJC-1295 shows that continuous exposure raises mean GH without necessarily preserving pulsatility — which is precisely the pharmacological trade-off that GH pulse biology predicts matters.

Ipamorelin (GHSR agonist)

Ipamorelin is a pentapeptide GHSR agonist developed at Novo Nordisk and first described by Raun and colleagues in 1998. The compound was characterized as a selective GH secretagogue that, unlike older GHRPs, did not significantly raise cortisol or prolactin in the studied models — a selectivity profile that was part of the stated rationale for its design (Raun et al., 1998).

Hexarelin, GHRP-2, GHRP-6

These older growth hormone releasing peptides, derived from Bowers's original synthetic series, are all GHSR agonists of varying potency and selectivity. Hexarelin and GHRP-2 in particular have been used extensively as pharmacological tools to probe the GHSR pathway, and both have been characterized in human pulsatility studies (Ghigo et al., 1997).

Why combinations are studied

Because GHRH and GHSR act synergistically, research protocols frequently combine a GHRH analog with a GHSR agonist — for example CJC-1295 with ipamorelin — to maximize GH release through dual receptor activation. This design mirrors the two-input biology of the somatotroph and produces larger GH responses than either agent alone in published experiments (Bowers et al., 1990).

Clinical research challenges

GH secretagogue research faces several structural difficulties that complicate the translation from pharmacological observation to meaningful outcomes.

Short-term GH elevation does not equal long-term outcome

A drug that reproducibly raises peak GH or mean 24-hour GH is pharmacologically interesting, but "raising GH" is not a clinical endpoint. Whether that elevation translates to measurable changes in body composition, metabolism, or health over time is a separate empirical question that requires different, longer, and larger studies.

IGF-1 as a downstream marker

Because IGF-1 has a long half-life (hours to days) compared to GH (minutes), IGF-1 is often used as a smoothed, integrated readout (a single stable number that reflects many hours of upstream activity) of GH action. It is more stable and easier to interpret but it is a surrogate — not every IGF-1 change corresponds to a clinically meaningful effect, and not every clinically meaningful GH effect is captured by IGF-1 alone (Ranke, 2005).

Body composition studies

Studies attempting to measure effects on fat mass, lean mass, or physical function require long durations (months), large sample sizes, and careful attention to confounders such as diet and exercise. Such studies are expensive and have been scarce for most of the experimental GH secretagogues, with the notable exception of the clinical development program for tesamorelin — a GHRH analog approved in HIV-associated lipodystrophy — which is the most complete data set of its type in the peer-reviewed literature (Falutz et al., 2007).

What the research has shown and what it hasn't

A fair summary of the GH secretagogue literature can be stated in four points.

• Robust GH elevation is shown. Multiple compounds in this class reliably raise circulating GH in controlled studies in humans. This is an established pharmacological effect, not a contested claim.
• IGF-1 elevation is often shown. Sustained administration of GHRH analogs and some GHSR agonists raises IGF-1 in controlled studies, with dose-dependent magnitudes.
• Long-term human efficacy on clinical endpoints is not established. For most compounds in this class — with tesamorelin as the exception — properly powered, long-duration, blinded trials of functional outcomes in healthy adults are not in the literature.
• Body composition effects over time are mixed. Where studies exist, they report modest and variable effects. The simple prediction "raise GH → lose fat → gain muscle" has not been cleanly validated for most experimental secretagogues.